Tykerb and Nosebleed - a phase IV clinical study of FDA data

Summary:

Nosebleed is reported as a side effect among people who take Tykerb (lapatinib ditosylate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Xeloda, and have Breast cancer female.

The phase IV clinical study analyzes which people have Nosebleed when taking Tykerb. It is created by eHealthMe based on reports of 12,186 people who have side effects when taking Tykerb from the FDA, and is updated regularly.

What is Tykerb?

Tykerb has active ingredients of lapatinib ditosylate. It is often used in breast cancer. eHealthMe is studying from 12,231 Tykerb users. Check the latest studies of Tykerb.

What is Nosebleed?

Nosebleed (bleeding from nose) is found to be associated with 2,080 drugs and 3,092 conditions by eHealthMe. Check the latest studies of Nosebleed.

On Jul, 13, 2026

12,186 people reported to have side effects when taking Tykerb.
Among them, 173 people (1.42%) have Nosebleed.

Among these 173 people:

* Approximation only. Some reports may have incomplete information.

Do you take Tykerb and have Nosebleed?

- Check whether Nosebleed is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tykerb:

Tykerb (12,231 reports)

Nosebleed treatments and more:

Nosebleed (92,075 reports)

How severe was Nosebleed and when was it recovered:

Nosebleed in Tykerb

Expand to all the drugs that have ingredients of lapatinib ditosylate:

Nosebleed and drugs with ingredients of lapatinib ditosylate (236 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tykerb:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nosebleed:

Nosebleed (2,080 drugs)

Browse all the conditions that are associated with Nosebleed:

Nosebleed (3,092 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lapatinib ditosylate (the active ingredients of Tykerb) and Tykerb (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.